Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linperlisib with or without rituximab in relapsed/refractory indolent non-Hodgkin lymphoma
CTR20231043Phase 3Active
- Sponsor
- Yingli Pharma
- Start
- Apr 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of linperlisib, rituximab in indolent lymphoma, sponsored by Yingli Pharma. Started Apr 2023; status: active.
02
Drugs
linperlisibrituximab
03
Conditions
indolent lymphoma
Beyond the preview
Go deeper on CTR20231043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231043.